Cusatuzumab ELISA Kit

Catalog No.

KDE01901

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD70 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Cusatuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Cusatuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Cusatuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Cusatuzumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

125 - 8,000 ng/mL

Sensitivity

85.26 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	4142.9	983.0	197.2	4400.0	992.5	215.9
Standard deviation	422.0	118.1	25.4	582.4	101.3	37.5
CV (%)	10.2	12.0	12.9	13.2	10.2	17.4

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

ARGX-110, CAS: 1399546-01-0

Background

Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study., PMID:37914483

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer., PMID:37648786

[Management of AML in the elderly]., PMID:36870810

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy., PMID:36779592

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment., PMID:36394119

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma., PMID:34726773

An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma., PMID:34405542

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial., PMID:34251873

An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia., PMID:33630233

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents., PMID:32601337

Document Download

Cusatuzumab ELISA Kit.pdf